IRL757
Small molecule
IRL757 is one of 13 small molecule programs targeting Apathy. It is currently in development.
1
Indications
3
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in Apathy
#DrugCompanyPhaseTrials
1Cialis
Eli LillyApproved
Azilect
TevaApproved
Neupro
UCBApproved
Dexedrine Spansule
Innovent Biologics (Suzhou) Co. Ltd.Approved
Risperdal
WWim Janssens
Phase 3
Provigil
NNuvo Research GmbH
Phase 3
Ulotaront
IIntra-Cellular Therapies, Inc.
Phase 3
Ritalin
NovartisPhase 2
Azilect
LundbeckApproved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IRL757. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]